



Rapidly advancing pipeline

Mast cell disorders


DISCOVERY EARLY-STAGE DEVELOPMENT LATE-STAGE DEVELOPMENT REGULATORY SUBMISSION APPROVED




Lung cancer




Breast cancer




Additional genomically defined cancers



Cancer immunotherapy



Research



■ ongoing or completed
 ■ planned

Updated as of February 16, 2023.

¹CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib and pralsetinib in Greater China.

²Approved in the U.S. for adults with advanced SM, including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL). Approved in Europe (AYVAKYT®) for adults with ASM, SM-AHN or MCL, after at least one systemic therapy.

³In collaboration with Roche.

⁴Received U.S. accelerated approval for adults with metastatic RET fusion-positive NSCLC. Received conditional marketing authorization in Europe for adults with advanced RET fusion-positive NSCLC not previously treated with a RET inhibitor.

⁵Zai Lab has exclusive rights to develop and commercialize BLU-945 and BLU-525 in Greater China.

⁶Approved in the U.S. for adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Approved in Europe (AYVAKYT®) for adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation.

⁷Received U.S. accelerated approval for advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.

GIST = gastrointestinal stromal tumors. NSCLC = non-small cell lung cancer. SM = systemic mastocytosis.

Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.

Not for promotional use.